Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation

Transplantation

Volumn 64, Issue 6, 1997, Pages 938-940

  Pratschke, Johann ^a   Neuhaus, Ruth ^a   Tullius, Stefan G ^a   Haller, Gary W ^a   Jonas, Sven ^a   Steinmueller, Thomas ^a   Bechstein, Wolf Otto ^a   Neuhaus, Peter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL;

ADULT; AGED; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORBIDITY; NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS;

EID: 0030850961     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199709270-00029     Document Type: Article

References (14)

1. Iwatsuki S, Starzl TE, Todo S, et al. Experience in 1000 liver transplants under cyclosporine and steroids immunosuppression. Transplant Proc 1988; 20: 8.
2. Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med 1994; 61: 308.
3. The European FK 506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
4. The US Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
5. Jonas S, Bechstein WO, Lemmens HP, et al. Conversion to tacrolimus after liver transplantation. Tranpl Int 1996; 9: 23.
6. Mueller AR, Platz KP, Bechstein WO, et al. Neurotoxicity after orthotopic liver transplantation: a comparison between cyclosporine and FK 506. Transplantation 1994; 58(2): 155.
7. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation: a comparison between cyclosporine and FK 506. Transplantation 1994; 58(2): 170.
8. Platz KP, Mueller AR, Jonas S, et al. Toxicity versus rejection - or why conversions between cyclosporine A and FK 506 were performed after liver transplantation. Clin Transpl 1995; 9: 146.
9. Winkler M, Ringe B, Jost U, et al. Conversion from cyclosporin to FK 506 after liver transplantation. Transpl Int 1993; 6: 319.
10. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056.
11. Jonas S, Kling N, Bechstein WO, et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporin based regimen: a controlled, prospective, randomized trial. Clin Transplant 1995; 9: 406.
12. Jordan ML, Shapiro R, Vivas CA, et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 27: 860.
13. Guckelberger O, Bechstein WO, Neuhaus R, et al. Cardiovascular risk-factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant (in press).
14. Abouljoud MS, Levy MF, Klintmalm GB, et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine a US multicenter trial. Transplant Proc 1995; 27: 1121.